Register Today!
June 11-13, 2017
Your Subtitle text

Past Conference 2013

Keynote Speakers


















Daniel B. Carr, MD, FABPM
Daniel B. Carr, MD, is a Professor at Tufts University School of Medicine, and he cofounded and serves as Director of the Pain Research, Education, and Policy (PREP) certificate and degree programs at Tufts University School of Medicine, the only one of its kind in the US. He has published and is known internationally for his contributions to pain research and education, evidence-based pain medicine, and social and political aspects of pain relief. He was Founding Editor of IASP’s Pain: Clinical Updates, lead editor for pain trials in the Cochrane Review Group on Pain, Palliative and Supportive Care, and serves on editorial boards of pain-related journals.


Sharon Walsh, PhD, MS
Sharon Walsh, PhD, MS is a Professor in the Departments of Behavioral Science and Psychiatry, and Director of the Center on Drug and Alcohol Research in the College of Medicine at the University of Kentucky. Dr. Walsh earned her MS and PhD from Rutgers University in Behavioral Neuroscience and completed her postdoctoral studies at Johns Hopkins University School of Medicine. She remained at Johns Hopkins for 13 years as a faculty member of the Behavioral Pharmacology Research Unit before leaving at the rank of Professor for the University of Kentucky in 2005. 
Dr. Walsh’s clinical research is focused on pharmacological issues in opioid and cocaine dependence and has been supported by the National Institute on Drug Abuse, private foundations and the pharmaceutical industry. She has conducted studies on the pharmacodynamic and pharmacokinetic characteristics of opioid treatment agents, including buprenorphine, methadone, LAAM and lofexidine, has conducted abuse liability evaluations of opioid analgesics, and has evaluated potential pharmacotherapies for efficacy and safety in the treatment of cocaine dependence. Dr. Walsh was the recipient of the Presidential Early Career Award for Scientists and Engineers (1997), the Joseph Cochin Young Investigator Award (2000) and the Betty Ford Award (2010). She has served on numerous review and advisory boards, including grant review panels for NIDA and the VA, advisory panels for the Food and Drug Administration, the National Institutes of Health and American Society for Addiction Medicine. She has served as President of the College on Problems of Drug Dependence and has published more than 90 manuscripts and book chapters on substance abuse.


Douglas Throckmorton, MD 
Douglas Throckmorton, MD, is the Deputy Director for Regulatory Programs in the Center for Drug Evaluation and Research (CDER) at the United States Food and Drug Administration (FDA). He is part of a senior leadership team that works to assure that safe and effective drugs are available to improve the health of people in the United States. Among his many responsibilities are coordination with other parts of the FDA on combination product development and coordination of CDER’s work with the White House and the Department of Health and Human Services on regulatory and educational strategies to combat the misuse and abuse of prescription drugs. He serves as the chair of the CDER Drug Safety Oversight Board and CDER’s Research Coordinating Committee. (via videoconference)


Conference Schedule
Condensed - Updated May 22, 2013 - Expanded Schedule Below


Sunday
June 9, 2013

 7:00 a.m.
Breakfast

 8:00 a.m.
Chairman's Welcome
Paul A. Sloan, MD
Seddon R. Savage, MD, MS
 
Keynote Address
Caring for Outliers in a Mean Minded World: Healthcare Reform and its Implications for Pain Management
Daniel B. Carr, MD, FABPM 

 9:00 a.m.

Multidimensional Pain Care
Seddon R. Savage, MD, MS


 9:20 a.m.

Interventional Pain Therapies
Ramsin Benyamin, MD
Presented by Paul A. Sloan, MD


 9:40 a.m.

Opioid Guidelines
Paul A. Sloan, MD


 10:10 a.m.
Break - EXHIBITS & POSTERS OPEN

 10:40 a.m.

Autonomy is the Cornerstone of Bioethics.

John Peppin, DO, FACP 
Michael E. Schatman, PhD, CPE

 11:40 a.m.
Inter-Professional Pain Education for Healthcare Professionals
Paul Arnstein, RN, PhD
Jeffry Shaefer, DDS 
Antje Barreveld, MD
Michele Matthews, PharmD, CPE, BCACP

 12:40 p.m.
Lunch-EXHIBITS & POSTERS OPEN

 2:10 p.m.
Improving the Quality and Safety of Opioid Analgesic Management in Primary Care
Daren Anderson, MD
Khushbu Khatri, BS
Terrence Tian, MPH

 3:10 p.m.
Pharmacogenetic Considerations in Opioid Prescribing
Michael J. Brennan, MD

 3:55 p.m.
Break-EXHIBITS & POSTERS OPEN

 4:25 p.m.
Opioids for Pediatric Patients

Stefan J. Friedrichsdorf, MD 
James Giordano, PhD, MPhil 


 6:00 p.m.
Patterns of Opioids Consumption
for Chronic Pain Treatment
in Children (2001-2010)

Pesach Shvartzman, MD 

 6:30 p.m.
End of Day 1


Monday,
 June 10, 2013

 7:00 a.m.
Breakfast

 8:00 a.m.
Keynote Address
An Update on the Pharmacology of Opioid Addiction and its Treatment: Challenges for Prescribers
 
Sharon Walsh, PhD, MS

 8:45 a.m.
Opioid Risk Assessment and Intervention for High-Risk Patients; How to Manage Challenging Pain Patients on Opioids for their Pain.
Robert N. Jamison, PhD

 9:45 a.m.
Pendulum is Swinging Back or New Barriers to Cancer Pain Management?
Natalie Moryl, MD

 10:15 a.m.
Break-EXHIBITS & POSTERS OPEN

 10:45 a.m.
Formulating a Rational Approach to Aberrancies Identified by Urine Drug Testing in Chronic Opioid Therapy
Suzie E. Rapp, MD
Jane C. Ballantyne, MD
Gary M. Reisfield, MD 
Daniel Krashin, MD

 12:15 p.m.
Selected Opioid Case Studies
Carol A. Warfield, MD (with panel above)

 1:00 p.m.
Lunch-EXHIBITS & POSTERS OPEN

 2:30 p.m.
Co-Prescribing Naloxone To Patients at High Risk of Opioid Overdose
Daniel Wermeling, PharmD, FCCP, FASHP

3:00 p.m.
Diffuse Noxious Inhibitory Control of Pain Modulation and Combination Opioid Therapy
Mellar P. Davis, MD, FCCP, FAAHPM

3:30 p.m.
Evaluation of the Immunological Properties of Therapeutic Opioids
Jason Boland, MD, PhD

 4:30 p.m.
Break-EXHIBITS & POSTERS OPEN

 5:00 p.m.
A Panel Discussion on PROP and the Future of Opioid Prescription
Jane C. Ballantyne, MD
Daniel B. Carr, MD, FABPM
Gilbert J. Fanciullo, MD (Host)

 6:30 p.m.
End of Day 2


Tuesday,
 June 11, 2013

 7:00 a.m.
Breakfast

 8:00 a.m.
Keynote Address (via videoconference)
FDA Update on Opioids and REMS

Douglas Throckmorton, MD

 8:45 a.m.
Trends in Law and Policy Affecting Opioid Prescribing
Michael C. Barnes, JD

 9:30 a.m.
Drug Testing Ethical Standards:
Is Voluntary Compliance Enough?

Richard Payne, MD
Catherine Sevier, DrPH
David Sevier

 11:00 a.m.
Break-EXHIBITS OPEN

 11:15 a.m.
Early Intervention  in Advanced Malignancy Decreases Opioid Requirements and Improves Quality of Life
Sushma Bhatnagar, MD

 11:45 a.m.
Physician Burnout: What it is, Why it is, and What you can do to combat it.
Gail Gazelle, MD, FACP, FAAHPM

 12:30 p.m.
Conference Wrap up
Adjourn

 12:45 p.m.
Post Conference Workshop:
Drug Testing Ethical Standards:
Is Voluntary Compliance Enough?

[Bray Lecture Hall]
Richard Payne, MD
Catherine Sevier, DrPH
David 
Sevier  

 1:00 p.m. - 2:00 p.m.

Reunion of past IAPCD members.
Conference registration required.
Call 781-899-2702 x 108 to RSVP


Full Conference Schedule

Expanded - Updated May 22, 2013

Photos in order
of appearance
In the program

Paul A. Sloan, MD

Seddon R. Savage, MD

Daniel B. Carr, MD

John Peppin, MD

Michael Schatman, MD

Paul Arnstein, PhD

Jeffry Shaefer, MD 

Antje Barreveld, MD

Michele Matthews, PharmD

Daren Anderson, MD

Khushbu Khatri, MD

Terrence Tian, PhD

Mellar Davis, MD

Stefan J. Friedrichsdorf, MD

James Giordano, MD

Pesach Shvartzman, MD

 
Sharon Walsh, PhD, MS

Robert Jamison, PhD
Natalie Moryl, MD

Suzie Rapp, MD

Jane Ballantyne, MD

Gary Reisfield, MD 

Daniel Krashin, MD

Carol Warfield, MD

Daniel Wermeling, Pharm.D.

Jason Boland, MD


Gilbert Fanciullo, MD

Douglas Throckmorton, MD

Michael Barnes, JD

Richard Payne, MD

Catherine Sevier

David Sevier

Sushma Bhatnagar, MD

Gail Gazelle, MD
Sunday, June 9, 2013
 
 7:00 a.m.

Breakfast - Registration Open 7:00am - 4:00pm (Registration also open Saturday, June 8, 2013, 12pm-3pm)

 8:00 a.m.
Chairman's Welcome
Paul A. Sloan, MD

Seddon R. Savage, MD, MS 

 8:15 a.m.
Keynote Address: 
Caring for Outliers in a Mean Minded World:
Healthcare Reform and its Implications for Pain Management

Daniel B. Carr, MD, FABPM 

 9:00 a.m.

Multidimensional Pain Care
A discussion on multidimensional care of pain and the need to address the whole person.
Seddon R. Savage, MD, MS 


 9:20 a.m.

Interventional Pain Therapies
A review of Interventional Pain Therapies in pain management.
Slides by Ramsin Benyamin, MD, Presented by Paul A. Sloan, MD

 9:40 a.m.

Opioid Guidelines
A review of the Opioid Guidelines as they apply to pain management.
Paul A. Sloan, MD


 10:10 a.m.
Break - EXHIBITS & POSTERS OPEN

 10:40 a.m.

Autonomy is the Cornerstone of Bioethics

Patients should choose options based on rational evaluation consistent with their values and beliefs.  However, in pain medicine, autonomy has unique implications. Patients typically take a very passive role, expecting to be “treated.”  However, in the treatment of pain, patients ideally play a more active role in their care.  This is especially true when opioids are used.
John Peppin, DO, FACP 
Michael Schatman, PhD, CPE


 11:40 a.m.
Inter-Professional Pain Education for Healthcare Professionals
This panel presentation will focus on inter-professional pain education for healthcare professionals using case-based methodology developed by the Harvard School of Dental Medicine and Brigham and Women’s Hospital Center of Excellence in Pain Education to stimulate learning about safe opioid prescribing practices created for dental, medical, nursing, and pharmacy students.
Paul Arnstein, PhD
Jeffry Shaefer, DDS 
Antje M. Barreveld, MD
Michele Matthews, PharmD, CPE, BCACP


 12:40 p.m.
Lunch-EXHIBITS OPEN

 2:10 p.m.
Improving the Quality and Safety of Opioid Analgesic Management
in Primary Care

Primary care providers treat patients with chronic pain regularly, but knowledge, confidence, and adherence to guidelines for opioid prescribing is variable.  We conducted an evaluation of opioid prescribing practice in a multisite community health center and implemented a two-part intervention to improve quality and safety of opioid management.
Daren Anderson, MD
Khushbu Khatri
Terrence Tian, MPH

 3:10 p.m.
Pharmacogenetic Considerations in Opioid Prescribing
Michael J. Brennan, MD

 3:55 p.m.
Break-EXHIBITS & POSTERS OPEN

 4:25 p.m.
Opioids for Pediatric Patients

Managing acute pain in children usually requires an integrative approach of pharmacology and integrative, supportive and rehabilitative therapies. Dr. Giordano will review the neuro-ontogeny of pain and analgesia to undergird neuroethical responsibilities in pediatric pain care. Dr. Friedrichsdorf will explicate these concepts and constructs in practice in a discussion of “broad-spectrum analgesia” with an emphasis on the evidence and rationale for effective, prudent and safe use of opioids in children.
Stefan J. Friedrichsdorf, MD 
James Giordano, PhD, MPhil 


 6:00 p.m.
Patterns of Opioids Consumption for chronic pain treatment
in children (2001-2010)

We intend to describe opioids consumption patterns among pediatric and adolescents in a large HMO in Israel.
Pesach Shvartzman, MD 


 6:30 p.m. 

End of Day 1

Monday, June 10, 2013

 7:00 a.m.
Breakfast - Registration Open 7:00am - 4:00pm

 8:00 a.m.
Keynote Address
An Update on the Pharmacology of Opioid Addiction and its Treatment: Challenges for Prescribers

Sharon Walsh, PhD, MS 

 8:45 a.m.

Opioid Risk Assessment and Intervention for High-Risk Patients;
How to Manage Challenging Pain Patients on Opioids for their Pain.

Robert N. Jamison, PhD

 9:45 a.m.
Pendulum is Swinging Back or New Barriers to Cancer Pain Management?
Natalie Moryl, MD

 10:15 a.m.
Break-EXHIBITS & POSTERS OPEN

 10:45 a.m.
Formulating a Rational Approach to Aberrancies Identified
by Urine Drug Testing in Chronic Opioid Therapy

The technology of urine drug testing in the monitoring of adherence in chronic opioid therapy is more advanced than the evidence of how to optimally utilize the test results.  This symposium will address available information to assist in guideline formation.
Suzanne E. Rapp, MD
Jane C. Ballantyne, MD, FRCA
Gary Reisfield, MD 
Daniel Krashin, MD

 12:15 p.m.
Selected Opioid Case Studies
Carol A. Warfield, MD (with panel above)

 1:00 p.m.
Lunch-EXHIBITS & POSTERS OPEN

 2:30 p.m.
Co-Prescribing Naloxone To Patients at High Risk of Opioid Overdose
  • Review epidemiology data identifying patients at high risk of prescription opioid overdose
  • Review literature describing Naloxone prescribing, dispensing and administration by lay persons in substance abuse harm reductions strategies
  • Review new laws and regulations embracing Naloxone prescribing, dispensing and administration in various states with high rates of opioid overdose
  • Considerations for implementing Naloxone prescribing in your practice.
Daniel Wermeling, PharmD, FCCP, FASHP 

3:00 p.m.
Diffuse Noxious Inhibitory Control of Pain Modulation
and Combination Opioid Therapy
Diffuse noxious inhibitory control is a downward inhibitory pathway important to pain modulation. This pathway has an intimate interaction with the rostral ventromedial medulla and which is mediated by opioids. Certain opioids such as morphine inhibit the pathway whereas oxycodone does not. DNIC is mediated through serotonin and the dorsal lamina funiculus. DNIC is impaired in pain processing disorders such as fibromyalgia and is also impaired by certain neuropathic disorders. Duloxetine improves conditioning pain modulation and increases pain thresholds and a subset of individuals with neuropathic pain. Combining agents which increase the efficiency of conditioning pain modulation as a presumed measure of DNIC with opioids may improve analgesic responses. Adaptive design trials which incorporate CPM phenotype may allow for selection of analgesics such as oxycodone and duloxetine in a target specific manner.
Mellar P. Davis, MD, FCCP, FAAHPM

 3:30 p.m.

Evaluation of the Immunological Properties of Therapeutic Opioids
Opioids have variable effects on immunity in diverse in vitro, animal and human models. This is the first study to systematically evaluate the immunological properties of therapeutic opioids using a profile of standardized immune assays. It showed that some opioids can suppress bacterial defense mechanisms, in a subject dependent manner.
Jason Boland, MD, PhD
 
 4:30 p.m.
Break-EXHIBITS & POSTERS OPEN

 5:00 p.m.
A Panel Discussion on PROP and the Future of Opioid Prescription
Jane C. Ballantyne, MD
Daniel B. Carr, MD, FABPM
Gilbert J. Fanciullo, MD (Host)

 6:30 p.m.
End of Day 2. 

Tuesday, June 11, 2013

 7:00 a.m.
Breakfast - Registration Open 7:00am - 10:00am

 8:00 a.m.
Keynote Address (via video conference)
FDA Update on Opioids and REMS
Douglas Throckmorton, MD

 8:45 a.m.
Trends in Law and Policy Affecting Opioid Prescribing
With increased public attention to opioid abuse in the United States, innovators, lawmakers, regulators, prosecutors, and even judges are eager to respond. The results are yielding demonstrable impacts on opioid prescribing.  This presentation analyzes current events affecting opioid prescribing, and identifies trends in state and federal law and policy.
Michael C. Barnes, JD

 9:30 a.m.
Drug Testing Ethical Standards: Is Voluntary Compliance Enough?
This presentation reviews a current Duke University study of questionable business practices in the drug testing laboratory industry within today’s complex legal/regulatory environment.  We will consider whether developing voluntary ethics standards can positively impact patient care and provide a remedy for business practices regarded by some as illegal or unethical.
Richard Payne, MD
Catherine Sevier, DrPH 
David Sevier

  11:15 a.m.
Early Intervention in Advanced Malignancy Decreases Opioid Requirements
and Improves Quality of Life
Patients with advanced malignancy commonly present with pain of varying severity. In a majority of these patients, pain can be effectively managed using an integrated systemic pharmacological approach with oral morphine being the cornerstone of treatment. However, with escalating doses, intolerable side effects of oral morphine may lead to patient dissatisfaction. When oral pharmacotherapy fails to adequately address the issue of pain or leads to insufferable side effects, neurolytic blocks of the sympathetic axis, local nerve block, radiofrequency ablation are usually used for pain alleviation. As these blocks may reduce oral analgesic requirement, a re-evaluation of their timing is merited.
Sushma Bhatnagar, MD

 11:45 a.m.
Physician Burnout: What it is, Why it is, and What you can do to combat it!
Numerous studies show high rates of burnout in a wide variety of specialties. Burnout affects physician quality of life and also has been shown to have a deleterious effect on many indices of patient care.  Since working in the field of chronic and terminal pain means challenging patients and high-stakes decision making, this topic is of particular importance. This session will look at data on burnout and physician wellness, and will provide practical strategies that participants can readily utilize in their day-to-day lives.
Gail Gazelle, MD, FACP, FAAHPM
 

 12:30 p.m. 
Conference Wrap up
Adjourn

 12:45 p.m.
Post Conference Workshop:
Drug Testing Ethical Standards:
Is Voluntary Compliance Enough?
Extended session on the presented topic.
[Bray Lecture Hall]
Richard Payne, MD 
Catherine Sevier, DrPH 
David Sevier 

 1:00 p.m. - 2:00 p.m.
Reunion of past IAPCD members.
Conference registration required.
Call 781-899-2702 x 108 to RSVP




Please
click here for the latest full Conference Brochure.

Please book mark this page and check back periodically.
Schedule Subject to change without notice